Decisions about treating community-acquired pneumonia

Annals of Internal Medicine

Volumn 142, Issue 3, 2005, Pages 215-216

  Mandell, Lionel ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LEVOFLOXACIN;

CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; DECISION MAKING; DISEASE SEVERITY; ETHNOLOGY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; OUTPATIENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOCIAL ASPECT;

EID: 13244291747     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-3-200502010-00014     Document Type: Review

References (15)

1. McMahon LF Jr, Wolfe RA, Tedeschi PJ. Variation in hospital admissions among small areas. A comparison of Maine and Michigan. Med Care. 1989;27:623-31.
2. Roos NP, Wennberg JE, McPherson K. Using diagnosis-related groups for studying variations in hospital admissions. Health Care Financ Rev. 1988;9:53-62.
3. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997;157:36-44.
4. Lave JR, Lin CJ, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Seminars in Respiratory and Critical Care Medicine. 1999;20:189-97.
5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820-37.
6. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78:45-51.
7. National Center for Health Statistics. National hospital discharge survey: annual survey 1990. Vital Health Stat. 1998;13:1-225.
8. Fine MJ, Singer DE, Marrie TJ, et al. Medical outcomes of ambulatory and hospitalized low risk patients with community acquired pneumonia. J Gen Intern Med. 1994;9:29.
9. Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156:1565-71.
10. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
11. Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia. A randomized trial in low-risk patients. Ann Intern Med. 2005;142:165-72.
12. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158:1350-6.
13. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283:749-55.
14. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717-23.
15. Goss CH, Rubenfeld GD, Park DR, Sherbin VL, Goodman MS, Root RK. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest. 2003;124:2148-55.